MX2022009807A - Metodos para tratar y prevenir arritmias por injerto. - Google Patents

Metodos para tratar y prevenir arritmias por injerto.

Info

Publication number
MX2022009807A
MX2022009807A MX2022009807A MX2022009807A MX2022009807A MX 2022009807 A MX2022009807 A MX 2022009807A MX 2022009807 A MX2022009807 A MX 2022009807A MX 2022009807 A MX2022009807 A MX 2022009807A MX 2022009807 A MX2022009807 A MX 2022009807A
Authority
MX
Mexico
Prior art keywords
treating
methods
engraftment
arrhythmias
subject
Prior art date
Application number
MX2022009807A
Other languages
English (en)
Spanish (es)
Inventor
Bjorn Knollmann
Robert Scott Thies
William Robb Maclellan
Kenta Nakamura
Charles E Murry
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2022009807A publication Critical patent/MX2022009807A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022009807A 2020-02-10 2021-02-09 Metodos para tratar y prevenir arritmias por injerto. MX2022009807A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972330P 2020-02-10 2020-02-10
PCT/US2021/017220 WO2021163037A1 (en) 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias

Publications (1)

Publication Number Publication Date
MX2022009807A true MX2022009807A (es) 2022-11-10

Family

ID=77291628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009807A MX2022009807A (es) 2020-02-10 2021-02-09 Metodos para tratar y prevenir arritmias por injerto.

Country Status (11)

Country Link
US (1) US20230077983A1 (enExample)
EP (1) EP4103206A4 (enExample)
JP (1) JP2023512843A (enExample)
KR (1) KR20220140532A (enExample)
CN (1) CN115484966A (enExample)
AU (1) AU2021218653A1 (enExample)
BR (1) BR112022015768A2 (enExample)
CA (1) CA3166678A1 (enExample)
IL (1) IL295236A (enExample)
MX (1) MX2022009807A (enExample)
WO (1) WO2021163037A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020245409A1 (en) * 2019-06-06 2020-12-10 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof
US20230250393A1 (en) * 2022-02-09 2023-08-10 University Of Washington Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
US20250101382A1 (en) * 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2024073499A2 (en) * 2022-09-28 2024-04-04 Bluerock Therapeutics Lp Compositions and methods for treating graft-related arrhythmia
WO2025137525A1 (en) * 2023-12-22 2025-06-26 Bluerock Therapeutics Lp Molecular identification of cardiomyocytes for cardiac cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192305A1 (en) * 2012-01-20 2013-08-30 Singapore Health Serv Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof in screening for agents
EP2833930B1 (en) * 2012-04-04 2018-05-30 University of Washington through its Center for Commercialization Systems and method for engineering muscle tissue
US9855317B2 (en) * 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
JP7333271B2 (ja) * 2017-03-15 2023-08-24 ユニヴァーシティ オブ ワシントン 心筋細胞の成熟および生着を増強するための方法および組成物
WO2020245409A1 (en) * 2019-06-06 2020-12-10 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof

Also Published As

Publication number Publication date
EP4103206A1 (en) 2022-12-21
CN115484966A (zh) 2022-12-16
JP2023512843A (ja) 2023-03-29
AU2021218653A1 (en) 2022-09-01
BR112022015768A2 (pt) 2022-11-22
US20230077983A1 (en) 2023-03-16
KR20220140532A (ko) 2022-10-18
EP4103206A4 (en) 2024-03-13
IL295236A (en) 2022-10-01
CA3166678A1 (en) 2021-08-19
WO2021163037A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
Mohamad-Hassani et al. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction
BR112022015768A2 (pt) Métodos de tratamento e prevenção de arritmias de enxerto
WO2007124127A3 (en) Structurally modified acellular tissue engineering scaffolds and methods of production
RU2014150508A (ru) МОДУЛЯЦИЯ hUTC ПРОВОСПАЛИТЕЛЬНЫХ МЕДИАТОРОВ ЛЕГОЧНЫХ И ПУЛЬМОНАЛЬНЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
CN102580141B (zh) 一种制备脱细胞真皮基质敷料的方法
WO2017043953A3 (es) Proceso de obtención de un compuesto de aspersión de células endoteliales microvasculares de piel y células madre mesenquimales y su método de aplicación para la regeneración tisular
WO2010108058A3 (en) Small molecule inhibitors of dusp6 and uses therefor
CN104938476A (zh) 一种骨软骨移植物保存液及其制备方法
CN108902128A (zh) 一种低温下动物组织和细胞的保存溶液及其使用方法
WO2023235775A3 (en) Collagen compositions and methods of use thereof
Drake et al. Acellular flexor tendon allografts: a new horizon for tendon reconstruction
CN102580152B (zh) 一种制备脱细胞骨的方法
CN102870778A (zh) 一种餐具消毒剂
JP2018532385A5 (enExample)
SA522431729B1 (ar) مركبات وطرق لعلاج أمراض متعلقة بالأوكسالات.
MX2015014704A (es) Compuestos, composiciones y métodos para el tratamiento de las enfermedades a través de la inhibición de la actividad del tgf-b.
Hu et al. Partial helix defect repair by use of postauricular advancement flap combined with ipsilateral conchal cartilage graft
CN108743618A (zh) 一种可注射性干细胞水凝胶制剂的制备方法及其应用
Tavassoli et al. Studies on marrow histogenesis I. The site of choice for extramedullary marrow implants
WO2020230997A3 (ko) 유두-유륜 복합체 재건용 임플란트 및 이의 제조방법
MX2021010088A (es) Composicion topica para mejorar la curacion de las dolencias oculares.
KR102366303B1 (ko) 식물성 복합 천연 계면활성제를 이용한 무세포 진피 기질 및 그 제조방법
CN100479868C (zh) 激光微孔猪去细胞真皮基质及其制备方法和应用
EP4647040A3 (en) Implants and systems for scarless mastopexy
CN109529106B (zh) 一种慢性创面修复基质的制备方法